For patients with bone‐only metastases, breast cancer subtype remained predictive of survival with median overall survival for LA of 39.1 months, LB of 32.9 months, TN of 8.6 months, and HER2 of 30.9 months (overall p < 0.001, by pairwise comparison all relationships remained significant except LB and HER2 (p = 0.181) (Figure 1). Here, ERBB2 is linked to breast carcinoma.